
Conference Coverage
about 1 month ago
From gene therapy to restoring sight: Highlights from EURETINA 2026about 2 months ago
Real-world VOYAGER data on faricimab in nAMD, DME, RVO at EURETINA 2026Trending on the Eye Care Network
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
BL1332 misses primary end point in phase 2 post-PRK ocular pain study
FLORetina-ICOOR 2026: AI moves from the image to the trial, the clinic, and the operating room
Why ST-100 is expanding from dry eye into corneal wound healing
Dry eye and Sjögren disease: Esen Akpek, MD, on screening and referral
Latest News

FLORetina-ICOOR 2026: FLO-ROP pathway brings ROP and pediatric retina to FLORetina 2026

FLORetina-ICOOR 2026: AI moves from the image to the trial, the clinic, and the operating room

ONL Therapeutics completes enrollment in Phase 2 GALAXY trial for geographic atrophy

Q&A: Caroline R. Baumal, MD, from academic retina to the C-suite and back | Eichenbaum Acorns

Longer anti-VEGF intervals in AMD, BRVO, and DME: 3 clinical cases

Shorts










Digital Edition





Podcasts
Continuing Medical Education
All News

Fluid decreased in vein occlusion, AMD, and DME on aflibercept 8 mg or faricimab.

The first-in-human study of the GalNAc-conjugated siRNA joins a fast-moving Stargardt pipeline as the FDA weighs the first potential approval for the disease.

Jayakrishna Ambati, MD, discusses phase 2 K8 findings in geographic atrophy, inflammasome targeting and K8 dosing and delivery.

Katherine Talcott, MD, discusses phase 2 VERONA findings on the vorolanib intravitreal insert in previously treated DME.

VeonGen aligns with FDA on phase 3 design for VG801, a dual-AAV Stargardt gene therapy, after uncontrolled phase 1/2 BCVA gains.

From the first BLA acceptance for a gene-agnostic optogenetic therapy to the first pivotal gene therapy trial in geographic atrophy, these are the retinal gene therapy milestones of 2026.

Clinical Forum cases examine symptoms, progression, and treatment response.

Duravyu missed wet AMD noninferiority twice, DAYBREAK met its end points, and optogenetics won the Nobel as son-vec posted 4-year RP data in an AAO-driven October.

Murtaza K. Adam, MD, reviews 3 patient cases to explore referral patterns, neovascularization after treatment, and barriers to care.

The FDA approved Lucamzi (ranibizumab-blrz), Xbrane's Lucentis biosimilar, for wet AMD and other serious eye conditions, with a US launch planned for 2027.

An estimated 9.6 million people in the US have diabetic retinopathy, and roughly 1 in 3 patients with diabetes miss annual eye exams as AI screening and new therapies reshape care.

Jordana G. Fein, MD, MS, points to agent selection, payer requirements, and real-world treatment response across 3 retina cases.

AREDS-based review links Mediterranean diet adherence to slower AMD and GA progression, as a complement to AREDS2 supplements.

Phase 3 SLO-RP Preserve will test whether oral NPI-001 slows photoreceptor loss in retinitis pigmentosa due to Usher syndrome.

FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites.
























